A multicenter clinical trial is needed to provide evidence-based treatment for fluid and insulin infusion rates for children with hyperosmolar DKA and HHS, to reduce the morbidity and mortality associated with these hyperglycemic crises. This evidence concerns the gene INS and hypotrichosis 1.